Shares of Hikma Pharmaceuticals PLC (LON:HIK – Get Free Report) have been given a consensus rating of “Moderate Buy” by the six research firms that are covering the company, Marketbeat Ratings reports. Two research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. The average twelve-month target price among analysts that have covered the stock in the last year is GBX 2,325 ($31.13).
Several research firms have recently weighed in on HIK. Deutsche Bank Aktiengesellschaft reiterated a “buy” rating and set a GBX 2,750 ($36.82) price target on shares of Hikma Pharmaceuticals in a research note on Tuesday, June 18th. Berenberg Bank raised shares of Hikma Pharmaceuticals to a “buy” rating and upped their price objective for the company from GBX 2,100 ($28.12) to GBX 2,400 ($32.14) in a report on Monday, September 2nd.
View Our Latest Report on Hikma Pharmaceuticals
Hikma Pharmaceuticals Price Performance
Hikma Pharmaceuticals Cuts Dividend
The business also recently declared a dividend, which was paid on Friday, September 20th. Stockholders of record on Thursday, August 15th were issued a $0.32 dividend. This represents a dividend yield of 1.37%. The ex-dividend date was Thursday, August 15th. Hikma Pharmaceuticals’s payout ratio is 9,687.50%.
Hikma Pharmaceuticals Company Profile
Hikma Pharmaceuticals PLC develops, manufactures, markets, and sells a range of generic, branded, and in-licensed pharmaceutical products. It operates through three segments: Injectables, Generics, and Branded. The Injectables segment provides generic injectable products primarily for use in hospitals.
See Also
- Five stocks we like better than Hikma Pharmaceuticals
- Quiet Period Expirations Explained
- CarMax’s Impressive Rally: What Investors Should Watch Next
- Following Congress Stock Trades
- MarketBeat Week in Review – 9/23 – 9/27
- Stock Splits, Do They Really Impact Investors?
- Wake Up to This Biotech Stock That Still Has Big Potential Upside
Receive News & Ratings for Hikma Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hikma Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.